Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP101 in Post-Menopausal Dry Eye
NCT03821415Phase 2Completed
- Sponsor
- Redwood Pharma
- Start
- Jan 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of RP101 in dry eye syndrome (DED) (4 arms), sponsored by Redwood Pharma. Primary endpoint: Schirmer's test type II (with anaesthesia) at 90 days. Started Jan 2019; status: completed.
02
Drugs
RP101
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03821415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821415.